下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

通过确定的逻辑门 CAR 策略克服靶向 CD86 的 CAR-T 细胞的自相残杀

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.

CAR-T 细胞治疗临床试验全景与发展趋势的全球多维分析

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

针对 Dickkopf-1-A2 复合物工程化的 T 细胞可用于治疗 HLA-A2(+) 实体瘤和血液系统肿瘤

T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2(+) solid and hematologic cancers.

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

CXCR4 修饰通过改善 B 细胞恶性肿瘤的肿瘤追踪与骨髓归巢增强 CAR-T 疗效

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies.

克服 CAR-T 与 CAR-NK 细胞疗法中的耐药与复发：从实验室到临床

Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

BCMA/CD19 双靶向 CAR-T 细胞疗法用于新诊断多发性骨髓瘤老年患者：一项 1 期研究

BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.